Business
Nuvec® Research update
Nuvec® Research update.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 1236W N4 Pharma PLC 15 April 2019 \n\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\n \n15 April 2019\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\n \nNuvec® Research update\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, provides an update on the development of Nuvec®.\n \nFurther to the announcement of 9 April 2019, disclosing inconsistencies in the efficacy of Nuvec® between various in vitro and in vivo studies, the Company is pleased to provide an update in light of the subsequent data review to determine appropriate next experiments, the aims of which are to resolve the inconsistencies and demonstrate repeatable in vivo data.\n \nIn reviewing the work done by collaborators and contract research organisations (\"CROs\") engaged by the Company, it has become clear that not only were there a number of variables between the studies (as determined by the collaborator or CRO) such as dosage, injection volume and source of antigen, but also the handling and preparation of Nuvec® may have differed materially from the original protocols used by the University of Queensland (\"UQ\") and developed by N4 Pharma.\n \nWith Nuvec® originating out of UQ and the original in vivo success having been achieved there, the Directors have decided that, in order to maximise the chances of success for future or repeat studies, the original data transfer reflecting UQ's successes needs to be more clearly documented. This will assist collaborators and CROs with their subsequent work. To that end, the Company will commission UQ to repeat its original studies to demonstrate repeated strong antibody response with the standard test antigen Ovalbumin (\"OVA\") and, in doing so, document clearly the preparation steps for Nuvec® prior to injection. In addition, the Company will expand the study to include further variables to strengthen the depth of data to emerge from this work. This study at UQ is expected to...